News

Scientific Publications: Standardised WT1 assay developed by the European LeukemiaNet (ELN) consortium

 

An international collaborative study coordinated by the European Leukemia Network (ELN) consortium on standardisation of WT1 testing for risk stratification in Acute Myeloid Leukemia has been published in the November 2009 issue of the Journal of Clinical Oncology.

The objective of this study was to select the best-performing WT1 assay and to assess the value of WT1 monitoring during AML treatment to estimate the risk of relapse.
Results of the study clearly show that the high performance WT1 assay designed by the ELN group is adapted to MRD assessment.
This specific assay developed and validated in the context of this study is commercialised by IPSOGEN under the name WT1 ProfileQuant^® Kit, and ref# PQPP-02-CE. It is CE marked and can be used with most RQ-PCR instruments.

Please don’t hesitate to contact us should you want to receive a reprint of this article or for any further information on our products.

---